Recent advances in hyaluronic acid-decorated nanocarriers for targeted cancer therapy

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The cluster-determinant 44 (CD44) receptor has a high affinity for hyaluronic acid (HA) binding and is a desirable receptor for active targeting based on its overexpression in cancer cells compared with normal body cells. The nanocarrier affinity can be increased by conjugating drug-loaded carriers with HA, allowing enhanced cancer cell uptake via the HA-CD44 receptor-mediated endocytosis pathway. In this review, we discuss recent advances in HA-based nanocarriers and micelles for cancer therapy. In vitro and in vivo experiments have repeatedly indicated HA-based nanocarriers to be a target-specific drug and gene delivery platform with great promise for future applications in clinical cancer therapy.

Related collections

Author and article information

Journal

Journal ID (nlm-journal-id): 9604391

Journal ID (pubmed-jr-id): 21634

Journal ID (nlm-ta): Drug Discov Today

Journal ID (iso-abbrev): Drug Discov. Today

Title: Drug discovery today

ISSN (Print): 1359-6446

ISSN (Electronic): 1878-5832

Publication date Nihms-submitted: 23 December 2016

Publication date (Electronic): 23 December 2016

Publication date (Print): April 2017

Publication date PMC-release: 01 April 2018

Volume: 22

Issue: 4

Pages: 665-680

Affiliations

[1 ]Use-inspired Biomaterials & Integrated Nano Delivery (U-BiND) Systems Laboratory, Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, 259 Mack Ave, Wayne State University, Detroit, MI 48201, USA

[2 ]Department of Chemistry, Lake Superior State University, 680 W. Easterday Avenue, Sault Ste. Marie, MI, USA

[3 ]The International Medical University, School of Pharmacy, Department of Pharmaceutical Technology, Jalan Jalil Perkasa 19, 57000 Kuala Lumpur, Malaysia

[4 ]Centre for Drug Delivery Research, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300, Kuala Lumpur, Malaysia

[5 ]National Institute of Pharmaceutical Education and Research (NIPER), Sarkhej – Gandhinagar Highway, Thaltej, Ahmedabad 380054, Gujarat, India

[6 ]Department of Pharmacy, School of Chemical Sciences and Pharmacy, Central University of Rajasthan, Bandarsindri, Ajmer, Rajasthan 305817, India

[7 ]Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University, School of Medicine, Detroit, MI 48201, USA

Author notes

Corresponding author: Iyer, A.K. ( arun.iyer@ 123456wayne.edu )

[*]

These authors contributed equally.

Article

Accession ID: PMC5413407 Pmcid ID: PMC5413407 Pmc-uid ID: 5413407 Manuscript ID: nihpa838735

DOI: 10.1016/j.drudis.2016.12.009

PMC ID: 5413407

PubMed ID: 28017836

SO-VID: 54c69088-95e5-439b-ba1a-6acfe645b59f

History

Comments

Comment on this article

scite_

Cited by 63

See all cited by

- Version 1